TY  - GEN
ID  - cogprints8934
UR  - http://cogprints.org/8934/
A1  - Bhise, R
A1  - Purohit, S
A1  - Lokanatha, D
A1  - Jacob, L
A1  - Suresh, TM
A1  - Govind Babu, K
A1  - Babu, S
A1  - Lakshmaiah, KC
Y1  - 2013/01/25/
N2  - Objective: To evaluate the efficacy of imatinib in chronic myeloid leukemia patients with variant translocations. Methods: Forty eight chronic myeloid leukemia patients carrying variant translocations and treated with imatinib at our institute were considered for the study. Survival and response rates were evaluated. Results: The median follow up was 48 months(m). Forty three (89.58%) patients achieved complete hematologic response. Thirty one (64.58%) patients achieved complete cytogenetic response and 19(39.58%) achieved major molecular response anytime during their follow up period. Only 18.75% of the patients achieved complete cytogenetic response and major molecular response within the stipulated time frames.The estimated overall survival at 48 m median follow up was 81.2%.The progression free survival was also 81.2% and the event free survival was 79.1%.There was no significant survival difference between low vs intermediate and high risk sokal group. Conclusion: We report suboptimal responses to imatinib in chronic myeloid leukemia with variant translocations. Further studies with imatinib and the newer more active drugs dasatinib and nilotinib are justified.
PB  - Kakkilaya BS
KW  - Chronic myeloid leukemia; Imatinib; Variant translocation
TI  - Chronic Myeloid Leukemia with Variant Chromosomal Translocations: Results of Treatment with Imatinib Mesylate.
AV  - public
ER  -

<script src='https://archive-bar.soton.ac.uk/archive-bar.js'></script>
<script src='https://archive-bar.soton.ac.uk/google-analytics.js'></script>